Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus Gemox in relapsed/refractory ENKTCL
ChiCTR2100049944Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Best complete remission rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR2100049944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049944.